Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Anti-tuberculosis drug resistance in Slovakia, 2018-2019: The first whole-genome epidemiological study

M. Dohál, V. Dvořáková, M. Šperková, I. Porvazník, AM. Cabibbe, A. Trovato, A. Spitaleri, EM. Rasmussen, K. Pršo, M. Škereňová, DM. Cirillo, I. Solovič, J. Mokrý

. 2022 ; 26 (-) : 100292. [pub] 20211220

Jazyk angličtina Země Velká Británie

Typ dokumentu časopisecké články, přehledy

Perzistentní odkaz   https://www.medvik.cz/link/bmc22010431

Objective: The resistance of Mycobacterium (M.) tuberculosis to antituberculosis drugs poses a major threat to global public health. Whole genome sequencing (WGS) is an increasingly preferred method in the diagnostics and monitoring of the transmission dynamics of resistant forms of tuberculosis (TB). The aim of the study was to, for the first time, use the sequencing-based analysis to study the transmission and resistance patterns of a systematic and recent collection of extensively drug resistant (XDR) and multidrug resistant tuberculosis (MDR-TB) isolates and to expand our knowledge about drug resistant (DR) TB epidemiological dynamics in Slovakia. Design: A total of 495 patients with pulmonary TB, who were referred to National Reference Laboratory for Mycobacteriology (Vyšné Hágy, Slovakia) in the years 2018-2019, were studied. Out of the total of 495 patients, 4 XDR-TB (0.8%) and 8 (1.6%) MDR-TB isolates were identified by conventional drug susceptibility testing on Löwenstein-Jensen solid medium and subjected to whole genome sequencing. Sequencing data were evaluated for molecular-epidemiological analysis and identification of resistance patterns. Results: Phylogenetic and cluster analysis showed extensive recent transmission events and the predominance of Euro-American lineage 4.7 in Slovakia. However, phylogenetic analysis revealed the circulation of several lineages that originally occurred in Eastern European countries. Resistance patterns for first- and second-line antituberculosis drugs characterized by whole genome sequencing were in high concordance with the results of phenotypic drug susceptibility testing. Conclusion: Forty percent of at least MDR-TB isolates were not genetically linked, indicating that appropriate measures should be taken to monitor and prevent the spread of drug-resistant tuberculosis within the country as well as in other regions.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22010431
003      
CZ-PrNML
005      
20240522093459.0
007      
ta
008      
220420e20211220xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jctube.2021.100292 $2 doi
035    __
$a (PubMed)35005254
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Dohál, Matúš $u Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia $7 xx0317390
245    10
$a Anti-tuberculosis drug resistance in Slovakia, 2018-2019: The first whole-genome epidemiological study / $c M. Dohál, V. Dvořáková, M. Šperková, I. Porvazník, AM. Cabibbe, A. Trovato, A. Spitaleri, EM. Rasmussen, K. Pršo, M. Škereňová, DM. Cirillo, I. Solovič, J. Mokrý
520    9_
$a Objective: The resistance of Mycobacterium (M.) tuberculosis to antituberculosis drugs poses a major threat to global public health. Whole genome sequencing (WGS) is an increasingly preferred method in the diagnostics and monitoring of the transmission dynamics of resistant forms of tuberculosis (TB). The aim of the study was to, for the first time, use the sequencing-based analysis to study the transmission and resistance patterns of a systematic and recent collection of extensively drug resistant (XDR) and multidrug resistant tuberculosis (MDR-TB) isolates and to expand our knowledge about drug resistant (DR) TB epidemiological dynamics in Slovakia. Design: A total of 495 patients with pulmonary TB, who were referred to National Reference Laboratory for Mycobacteriology (Vyšné Hágy, Slovakia) in the years 2018-2019, were studied. Out of the total of 495 patients, 4 XDR-TB (0.8%) and 8 (1.6%) MDR-TB isolates were identified by conventional drug susceptibility testing on Löwenstein-Jensen solid medium and subjected to whole genome sequencing. Sequencing data were evaluated for molecular-epidemiological analysis and identification of resistance patterns. Results: Phylogenetic and cluster analysis showed extensive recent transmission events and the predominance of Euro-American lineage 4.7 in Slovakia. However, phylogenetic analysis revealed the circulation of several lineages that originally occurred in Eastern European countries. Resistance patterns for first- and second-line antituberculosis drugs characterized by whole genome sequencing were in high concordance with the results of phenotypic drug susceptibility testing. Conclusion: Forty percent of at least MDR-TB isolates were not genetically linked, indicating that appropriate measures should be taken to monitor and prevent the spread of drug-resistant tuberculosis within the country as well as in other regions.
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Dvořáková, Věra $u National Reference Laboratory for Mycobacteria, National Institute of Public Health, Praha, Czech Republic
700    1_
$a Šperková, Miluše $u National Reference Laboratory for Mycobacteria, National Institute of Public Health, Praha, Czech Republic
700    1_
$a Porvazník, Igor $u National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia, Faculty of Health, Catholic University, Ružomberok, Slovakia $u Faculty of Health, Catholic University, Ružomberok, Slovakia
700    1_
$a Cabibbe, Andrea Maurizio $u Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Trovato, Alberto $u Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Spitaleri, Andrea $u Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Rasmussen, Erik Michael $u International Reference Laboratory of Mycobacteriology, Statens Serum Institut, Copenhagen, Denmark
700    1_
$a Pršo, Kristián $u Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia
700    1_
$a Škereňová, Mária $u Biomedical Center Martin, Department of Molecular Medicine, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia, Department of Clinical Biochemistry, Jessenius Faculty of Medicine in Martin, Comenius University in Bratislava, Slovakia
700    1_
$a Cirillo, Daniela Maria $u Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
700    1_
$a Solovič, Ivan $u National Institute of Tuberculosis, Lung Diseases and Thoracic Surgery, Vyšné Hágy, Slovakia, Faculty of Health, Catholic University, Ružomberok, Slovakia
700    1_
$a Mokrý, Juraj $u Department of Pharmacology and Biomedical Center Martin, Jessenius Faculty of Medicine, Comenius University, Slovakia
773    0_
$w MED00209095 $t Journal of clinical tuberculosis and other mycobacterial diseases $x 2405-5794 $g Roč. 26 (20211220), s. 100292
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35005254 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20220420 $b ABA008
991    __
$a 20240522093455 $b ABA008
999    __
$a ind $b bmc $g 1784588 $s 1161629
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 26 $c - $d 100292 $e 20211220 $i 2405-5794 $m Journal of clinical tuberculosis and other mycobacterial diseases $n J Clin Tuberc Other Mycobact Dis $x MED00209095
LZP    __
$a Pubmed-20220420

Najít záznam

Citační ukazatele

Možnosti archivace